Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zai Lab Ltd ADR (ZLAB)

Zai Lab Ltd ADR (ZLAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,071,315
  • Shares Outstanding, K 111,963
  • Annual Sales, $ 398,990 K
  • Annual Income, $ -257,100 K
  • EBIT $ -228 M
  • EBITDA $ -220 M
  • 60-Month Beta 0.83
  • Price/Sales 4.52
  • Price/Cash Flow N/A
  • Price/Book 2.80

Options Overview Details

View History
  • Implied Volatility 105.18% (+18.76%)
  • Historical Volatility 38.91%
  • IV Percentile 95%
  • IV Rank 50.68%
  • IV High 165.65% on 01/02/26
  • IV Low 43.03% on 06/11/25
  • Expected Move (DTE 6) 3.40 (18.33%)
  • Put/Call Vol Ratio 5.75
  • Today's Volume 27
  • Volume Avg (30-Day) 274
  • Put/Call OI Ratio 3.09
  • Today's Open Interest 5,575
  • Open Int (30-Day) 6,381
  • Expected Range 15.15 to 21.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.38
  • Number of Estimates 1
  • High Estimate -0.38
  • Low Estimate -0.38
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +52.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.82 +10.29%
on 12/16/25
19.32 -3.99%
on 01/07/26
-0.15 (-0.80%)
since 12/09/25
3-Month
16.82 +10.29%
on 12/16/25
32.76 -43.38%
on 10/10/25
-14.15 (-43.27%)
since 10/09/25
52-Week
16.82 +10.29%
on 12/16/25
44.34 -58.16%
on 06/12/25
-5.75 (-23.66%)
since 01/08/25

Most Recent Stories

More News
Targeted Precision: Rare Disease Assets Attract Record Regulatory Momentum

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market...

ONCY : 0.9677 (-2.41%)
IDYA : 37.38 (+2.61%)
ZLAB : 18.55 (+0.27%)
CHRS : 1.6900 (+10.46%)
HALO : 72.47 (+0.47%)
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYROâ„¢ (repotrectinib) for Patients with NTRK-Positive Solid Tumors

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib)...

ZLAB : 18.55 (+0.27%)
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the 44th Annual J.P. Morgan Healthcare Conference on...

ZLAB : 18.55 (+0.27%)
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia

COBENFY is the first major advance in schizophrenia treatment in decades, offering a novel mechanism of action distinct from other therapies COBENFY has already been included...

ZLAB : 18.55 (+0.27%)
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis

- ZL-1503, a promising treatment for moderate-to-severe atopic dermatitis and other Type 2 helper T-cell (Th2)-driven diseases, strengthens Zai Lab’s growing global pipeline ...

ZLAB : 18.55 (+0.27%)
Zai Lab Announces Updates to China’s National Reimbursement Drug List

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by China’s National...

ZLAB : 18.55 (+0.27%)
Novel Immunotherapy Breakthroughs Advance Blood Cancer Treatment

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing...

ZLAB : 18.55 (+0.27%)
GTBP : 0.6770 (-0.44%)
ROIV : 21.98 (+0.92%)
CCCC : 2.14 (-2.28%)
BMY : 55.86 (-0.07%)
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates

– Zocilurtatug pelitecan (zoci, DLL3 ADC) (formerly ZL-1310) data presented at Triple Meeting in October continues to demonstrate first- and best-in-class potential, supporting the recent initiation...

ZLAB : 18.55 (+0.27%)
Zai Lab Announces Participation in Investor Conferences in November and December 2025

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November and December 2025: ...

ZLAB : 18.55 (+0.27%)
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study

- Robust responses observed in heavily pre-treated patients with a 68% ORR for 1.6 mg/kg in second-line setting -Compelling activity in patients with baseline brain metastases...

ZLAB : 18.55 (+0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China....

See More

Key Turning Points

3rd Resistance Point 19.69
2nd Resistance Point 19.42
1st Resistance Point 18.99
Last Price 18.55
1st Support Level 18.29
2nd Support Level 18.02
3rd Support Level 17.59

See More

52-Week High 44.34
Fibonacci 61.8% 33.83
Fibonacci 50% 30.58
Fibonacci 38.2% 27.33
Last Price 18.55
52-Week Low 16.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar